Indivior Pharmaceuticals: stockholders approve share issuance for merger

What happened Indivior Pharmaceuticals, Inc. reported that at a special meeting of its stockholders on Oct 15, 2026, stockholders approved the Indivior Share Issuance Proposal to approve the issuance of Indivior Shares in connection with the Merger as contemplated by the Merger Agreement, including for purposes of complying with Nasdaq Rule 5635. The filing says the proposal is described in greater detail in Indivior’s definitive joint proxy statement/prospectus filed with the SEC on Sep 11, 2026.

Key details

• At the close of business on Sep 4, 2026 (the record date), there were 118,031,934 Indivior Shares outstanding and entitled to vote.
• 91,206,182 Indivior Shares were present in person or represented by proxy at the meeting, representing 77.27% of Indivior Shares outstanding and entitled to vote (a quorum).
• Final vote on the Indivior Share Issuance Proposal: For 85,455,705; Against 5,563,744; Abstain 186,733; Broker non-vote N/A.
• A proposal to approve one or more adjournments, if needed, was not required and no vote was taken on that proposal.

Why it may matter This filing is Item 5.07 — submission of matters to a vote of security holders — and reports the voting results for the Indivior Share Issuance Proposal, which approves issuance of shares in connection with the Merger and addresses compliance with Nasdaq Rule 5635. The filing does not show why the insider traded or why the company acted.